Oramed Pharmaceuticals Inc. — Director's Dealing 2024

Jun 21, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2024-06-21

Reporting Person: Gabay Avraham (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-21	Common Stock	A	140040	—	Acquired	0	Direct

Footnotes

F1: Represents a grant of 140,040 Restricted Stock Units ("RSUs"), of which 93,360 will vest on June 18, 2026 and the remaining 46,680 will vest in four equal quarterly installments of 11,670 starting September 18, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.